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Abstract 
Objective: The current study aims to evaluate 
the efficacy of vaginal misoprostol before 
elective cesarean section (ECS) for preventing 
the occurrence of neonatal respiratory distress 
(RD). 
Materials and Methods: A randomized controlled 
trial (NCT03239327) was carried out in a 
tertiary-care university-affiliated hospital 
between June 2016 and August 2017. All 
eligible pregnant women scheduled for ECS 
were randomly allocated in a 1:1 ratio to two 
groups.  One group, the Misoprostol group, 
received a misoprostol 50 mcg vaginal tablet 60 
minutes before ECS while the other, the Control 
group, received no drugs before ECS. The 
primary outcome was the rate of neonatal RD 
among the study groups. 
Results: The study included 146 women in each 
arm, with no significant difference between the 
baseline characteristics of members in each 
group.  Primary outcomes resulted in 22 (15.1%) 
newborns in the misoprostol group having RD at 
birth versus 44 (30.1%) newborns with RD in the 
control (P =0.02). No differences were found 
between the groups regarding the need for 
neonatal intensive care unit (NICU) admission 
(P =0.61), duration of NICU stay (P =0.08) and 
neonatal mortality rate (P =0.73). 
Conclusion: Prophylactic vaginal misoprostol at 
a dose of 50 mcg administered 60 minutes 
before ECS could reduce the rate of neonatal 
RD and improve the neonatal respiratory 
outcomes. 
1Department of Obstetrics and Gynecology, 
Faculty of Medicine, Assiut University, Egypt 
 
Introduction 
Cesarean section (CS) is considered 
one of the most common surgical 
procedures worldwide as its rate has 
steadily increased over the last few 
years.1 Additionally, neonatal respiratory 
distress (RD) resulting in death, which 
occurs in about 27% of cases,4 is more 
prevalent among infants delivered by 
elective cesarean section (ECS) than 
after emergency CS or vaginal 
delivery.2,3 The most frequent clinical 
presentations of neonatal RD are 
respiratory distress syndrome (RDS), 
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transient tachypnea of the newborn 
(TTN) and persistent pulmonary 
hypertension of the newborn (PPHN). 
RDS occurs in 1% of pregnancies due 
to qualitative or quantitative deficiency 
of surfactant production.4 TTN is mainly 
attributed to delayed resorption of 
pulmonary fluid as a result of imperfect 
catecholamine surge.5 
Catecholamines are known to promote 
surfactant secretion by acting on beta-
adrenergic receptors in fetal lungs to 
increase their ability to reabsorb lung 
fluid.6   However, infants born at term by 
ECS are deprived of the hormonal 
changes that protect them from RD.7 
This could be attributed to a defective 
catecholamine surge occurring at the 
onset of labor that increases surfactant 
production and lung fluid absorption.8 
This allows the neonatal respiratory 
system to be adapted for extra-uterine 
life. Prostaglandin administration before 
delivery can stimulate the 
catecholamine surge and thus reduce 
neonatal RD.9 The most suitable time for 
its administration to provoke this effect 
before CS is still unknown. A previous 
study reported that vaginal 
administration of prostaglandin E2 gel 
60 minutes before CS significantly 
increased the catecholamine levels in 
the fetal blood.9 
A recent Cochrane review (2013) on the 
effect of prostaglandins before CS for 
preventing neonatal RD included only a 
single study on the application of vaginal 
prostaglandin E2 gel.10 They expressed 
the need for further trials to determine 
the impact of prostaglandins on 
neonatal respiratory complications after 
ECS. A recent study by Khairy et al., 
2017, reported that administration of 
200 mcg of vaginal misoprostol at term, 
one hour before ECS, significantly 
reduced the occurrence of neonatal 
RD.11 
Misoprostol is a prostaglandin E1 analog 
that is available for cervical ripening 
before a variety of obstetric and 
gynecologic procedures.12-14 One of its 
advantages is that it can be 
administered through multiple routes 
(oral, buccal, sublingual, vaginal, 
rectal).15 However, an ideal dose and 
route for the administration of 
misoprostol remains unclear, with more 
than 30 different dosage regimens for its 
use among pregnant women described 
in the literature.16 
Therefore, the current study aims to 
evaluate the efficacy of vaginal 
misoprostol before ECS for preventing 
the occurrence of neonatal RD. 
Materials and Methods 
Study type, settings and duration 
The current study was a randomized, 
controlled trial (RCT) clinically registered 
at ClinicalTrials.Gov (NCT03239327). 
The study was conducted in Assiut 
University Women’s Health Hospital, 
Egypt, between June 2016, and August 
2017. The Assiut Medical School Ethical 
Review Board approved the study 
protocol. Written consent was obtained 
from all study participants before 
enrollment. 
Study participants 
We invited all pregnant women who 
attended the Antenatal Care Clinic of 
our hospital and were scheduled for 
ECS to participate in the study. Inclusion 
criteria limited study participants to 
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women aged 18 years or older, with an 
uncomplicated pregnancy at 34 to 37 
weeks gestation, both with or without 
previous CS, carrying a singleton fetus 
with no major anomalies.  Gestational 
age was confirmed with reliable early 
ultrasound measurement of crown-rump 
length. We excluded women with 
medical disorders, fetal distress or 
demise, and those scheduled for 
emergency CS. Additionally, women 
with any contraindication or sensitivity to 
prostaglandins and those who declined 
participation in the study were excluded. 
Sample size 
Sample size calculation was based on 
the incidence of neonatal severe RD 
requiring admission to a neonatal 
intensive care unit (NICU). Le Ray, et 
al., estimated the frequency of severe 
RD in ECS deliveries between 34 and 
37 weeks to be 28 %.17 The 292 
included study participants were divided 
into groups of 146 each.  This sample 
size and the use of a two-sided chi-
square test with α error of 0.05 
suggested 80 % power to detect a 50% 
reduction in the RD rate after vaginal 
administration of misoprostol (OR =0.50) 
(Epi-info™, CDC, USA. 2016). 
Randomization  
Women who met the inclusion criteria 
were randomly allocated, using sealed, 
coded, opaque and sequentially 
numbered envelopes containing 
computer generated random numbers 
into either the study group or the control 
group. One of the investigators retained 
the randomization envelopes and did 
not share in patients counseling or care. 
Allocation was never changed after 
patients were place in either the study or 
control group. The study was open-
labeled so neither the investigators nor 
the participants were blinded. 
Study intervention 
At the time of recruitment, one of the 
study investigators collected basic data 
about participants including number of 
previous miscarriages, number of 
previous CS, indication of current ECS 
and gestational age at delivery.  All 
women received two intramuscular 
doses of 12 mg dexamethasone 
(Epidron®;Eipico Pharma, Egypt) 12 
hours apart, 48 hours before the 
scheduled time of ECS. 
Eligible participants were randomly 
allocated in a 1:1 ratio to two groups. 
The study group consisted of women 
who received a misoprostol vaginal 
tablet 50 mcg (Misotac®; Sigma Pharma, 
SAE, Egypt) 60 minutes before ECS. 
The control group consisted of women 




monitoring was carried out after 
misoprostol administration to detect any 
evidence of uterine hyperstimulation 
and/or fetal distress. The surgical and 
anesthetic teams were in a state of 
complete readiness for the CS from the 
time of misoprostol administration. The 
anesthetic and surgical techniques were 
standardized for all women. Spinal 
anesthesia was used with preload of 
500 ml saline and continuation of 
intravenous fluids throughout the 
operation. Regarding the surgical 
technique, all deliveries were performed 
through a transverse lower uterine 
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segment CS with delayed cord clamping 
(30 seconds after delivery). The same 
anesthetic and surgical team performed 
all the operations. 
All deliveries were attended by a 
neonatology specialist, and details of 
the resuscitation at the operative theatre 
were recorded. Neonatal birth weight, 
heart rate, respiratory rate (RR), and 
Apgar scores at 1 and 5 minutes were 
recorded. Apgar score is usually used to 
represent the neonate’s ability to initiate 
and maintain breathing after birth on a 
scale from zero to 10.18 Apgar scores 
less than 3 indicate severe RD while 
scores between 4 and 6 indicate mild to 
moderate RD. There is no RD when the 
scores are between 7 and 10.   
All neonates were assessed for signs of 
RD such as the presence of apnea, 
tachypnea, central cyanosis, chest wall 
retraction and nasal flaring19 or signs of 
TTN (defined as a period of rapid 
breathing higher than the normal range 
of 40-60 times per minute).20 All 
interventions performed by the 
pediatrician were recorded including, 
use of ambu-bag, endotracheal 
intubation, admission to the NICU and 
length of stay. Any case of neonatal 
mortality was recorded. The neonatal 
mortality rate was defined as the 
number of neonates that died from 
respiratory morbidity within one month 
of delivery. 
Study outcomes 
The primary outcome of this study was 
the rate of neonatal RD defined as 
RR>60 cycles per minute and/or signs 
of RD.4 Secondary outcomes included 
Apgar scores at 1 and 5 minutes, the 
respiratory rate of the newborn, the 
incidence of apnea, the incidence of 
TTN, the need for mechanical ventilation 
of the neonate either by ambu-bag 
resuscitator or endotracheal intubation, 
the incidence of admission to NICU, the 
duration of NICU stay and the neonatal 
mortality rate. 
Statistical analysis 
Data entry and statistical analysis were 
done using SPSS software, Chicago, IL, 
USA, version 21. Categorical data were 
presented as frequency and percentage. 
Comparison between data in both 
groups was done by chi-square test. 
Continuous variables were compared 
using Student's t-test in the form of 
means ± standard deviation. Odds Ratio 
(OR) was estimated to evaluate clinical 
benefits from the administration of the 
drug used. Multivariate logistic 
regression analysis for the parameters 
affecting the rate of neonatal RD was 
carried out. P value < 0.05 was 
considered significant. 
Results 
We invited 304 women to participate in 
the study. Ten women were excluded as 
they did not meet the eligibility criteria. 
Moreover, two women declined 
participation in the study. We randomly 
assigned 292 women into the two study 
groups; 146 women in each arm (Figure 
1: study flow chart).  
Table 1 shows that both groups were 
homogenous regarding the baseline 
characteristics. The most common 
indication of ECS in both groups was 
repeat CS (77.4% of cases). No cases 
of uterine hyperstimulation or dehiscent 
CS scars were observed in either group. 
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Figure 1: The study flowchart. 
Table 1: The baseline characteristics of the study participants 





Age (years) 27.52 ± 6.0 27.92 ± 5.95 0.64 
Parity 2.36 ± 1.87 2.10 ± 1.92 0.33 
Num. of previous miscarriages 1.01 ± 0.63 1.06 ± 0.75 0.47 
Num. of previous CS 1.45 ± 1.28 1.38 ± 1.32 0.70 
Gestational age at delivery (weeks) 35.81 ± 0.29 35.72 ± 0.39 0.19 
 
CS; Cesarean section, All data are presented as mean ± standard deviation 
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Table 2 shows neonatal condition at 
birth. The respiratory rate in the 
misoprostol group was significantly 
lower than in the control group (43.2±8.3 
vs. 54.1±10.6 cycles/min., respectively, 
p=0.01). There was no difference 
between the study and control groups 
regarding neonatal birth weight, heart 
rate, and Apgar scores at 1 & 5 minutes. 
Moreover, there was no difference 
regarding fetal gender in either group; 
77 (52.7%) were male and 69 (47.3%) 
were female in the misoprostol group 
versus 71 (48.6%) males and 75 
(51.4%) females in the control group (p= 
0.92). 
Table 2: The neonatal condition at birth in both study groups 





Neonatal birth weight (grams) 2928 ± 356 2884 ± 412 0.47 
Heart rate (beats/min.) 134.6 ± 11.3 131.2 ± 11.6 0.41 
Respiratory rate (cycle/min.) 43.2 ± 8.3 54.1 ± 10.6 0.01* 
Apgar score at 1 min. 8.7 ± 1.4 8.5 ± 1.5 0.46 
Apgar score at 5 min. 9.4 ± 0.5 9.3 ± 0.6 0.31 
Duration of NICU stay (days) 3.1 ± 1.2 3.3 ± 1.5 0.08 
NICU; neonatal intensive care unit, All data are presented as mean ± standard deviation 
* Statistical significant difference 
Table 3: The neonatal outcomes in both study groups 







 (95% confidence 
interval) 
P-value 
Chest wall retraction  20 (13.7) 27 (18.5) 0.8 (0.62 - 1.09) 0.22 
Nasal flaring  12 (8.2) 17 (11.6) 0.8 (0.6 -1.1) 0.34 
Cyanosis  4 (2.7) 7 (4.8) 0.77  (0.49 - 1.23) 0.48 
Apnea  1 (0.7) 6 (4.1) 0.57 (0.41 - 0.79) 0.04* 
Respiratory distress 
Severe (Apgar ≤ 3) 












TTN 22 (15.1) 38 (26) 0.7 (0.56 - 0.91) 0.01* 
Need for ambu-bag 2 (1.4) 6 (4.1) 0.65 (0.43 - 0.99) 0.24 
Need for intubation 0 4 (2.7) 0.49 (0.43- 0.55) 0.04* 
Need for NICU admission 16 (11) 19 (13) 0.9 (0.65- 1.26) 0.61 
Neonatal mortality rate 3 (2) 4 (2.7) 0.87 (0.45 - 1.67) 0.73 
NICU; neonatal intensive care unit, TTN; transient tachypnea of newborn 
All data are presented as number (%)  * Statistical significant difference 
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Overall, the primary outcomes showed 
that 22 newborns (15.1%) in the 
misoprostol group had RD at birth 
versus 44 newborns (30.1%) in the 
control group, with a statistically 
significant difference between the two 
groups (p=0.02). The incidence of TTN 
and apnea were significantly higher in 
the control group than the misoprostol 
group (p=0.01 and 0.04 respectively). 
Other signs of RD such as chest wall 
retraction, nasal flaring and cyanosis 
showed no significant difference 
between each group (Table 3).  
Only two newborns in the misoprostol 
group (1.4%) needed assisted 
ventilation by ambu-bag versus six 
newborns (4.1%) in the control group, 
with no statistical difference (p=0.24). 
On the other hand, four newborns 
(2.7%) in the control group needed 
endotracheal intubation versus none in 
the misoprostol group, with a statistically 
significant difference (p=0.04). Finally, 
there were no differences between the 
two groups regarding the need for NICU 
admission (p=0.61), duration of NICU 
stay (p=0.08) and neonatal mortality rate 
(p=0.73) (Table 3). 
Multivariate logistic regression analysis 
done for the predictors of neonatal RD 
revealed that maternal age, parity and 
indication of CS were not predictors for 
occurrence of neonatal RD. In fact, 
gestational age at delivery and use of 
misoprostol before CS were the only 
parameters that independently affected 
the rate of neonatal RD (p=0.001 and 
0.026, respectively) (Table 4).  
 










B Std. Error 
(Constant) 41.020 8.475   0.000 
Age 0.022 0.030 0.053 1.022 0.466 
Parity  0.744 0.464 0.56 0.475 0.109 
Indication of CS 0.631 0.744 0.718 0.958 0.532 
Gestational age  -1.169 0.237 0.523 0.311 0.001* 
Use of misoprostol -0.805 0.362 -0.339 0.447 0.026* 
* Statistical significance at P <0.05 
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Discussion
In this randomized controlled study, we 
demonstrated that administration of 50 
mcg vaginal misoprostol 60 minutes 
before ECS at 34 to 37 weeks gestation 
may decrease the rate and severity of 
neonatal RD. To the best of our 
knowledge, this is the first study 
evaluating the effect of misoprostol 
administration on neonatal respiratory 
outcomes before ECS at 34 to 37 weeks 
gestation.  
RD is the main cause of early neonatal 
morbidity and mortality and frequently 
accounts for the high cost of neonatal 
intensive care.21 Thus, term newborn 
delivery by ECS rather than vaginally 
leads to a two- to four-fold increase in 
risk for neonatal respiratory morbidity.22 
Earlier animal studies demonstrated the 
beneficial effect of prostaglandins on the 
respiratory function. Torday et al., 
reported that prostaglandin E2 
integrated the effects of fluid distension 
and glucocorticoids on lung 
maturation.23 Additionally, Zaremba et 
al., reported that administration of 
prostaglandin F2 alpha analogue to 
pregnant cows before labor accelerated 
fetal lung maturation and improved 
respiratory function after birth.24 
With the current rapid rise of CS 
worldwide, we recognize the urgent 
need for studying the neonatal 
respiratory complications. While ECS is 
a well-known risk factor for different 
forms of neonatal RD, other 
confounding factors may add to the 
development of neonatal RD after CS. 
These may include neonatal gender, 
birth weight, type of anesthesia, 
administration of steroids and maternal 
medical disorders.25 In the current study, 
women with medical disorders were 
excluded. Additionally, all participants 
received a prophylactic dose of 
corticosteroids and delivered under 
spinal anesthesia. Furthermore, there 
were no significant differences between 
the study and control groups regarding 
neonatal gender or birth weight. 
The Cochrane review published in 2013 
included only one study about the use of 
prostaglandins before CS for preventing 
neonatal RD.10 In 2004, a RCT involving 
36 women, by Singh and colleagues in 
Australia, showed that prophylactic 
administration of 2 mg vaginal 
prostaglandin E2 gel 60 minutes before 
ECS at ≥ 38 weeks gestation 
significantly increased noradrenaline 
concentrations in umbilical arterial blood 
with no difference in adrenaline 
concentration nor the arterial and 
venous pH.9 In this study, only one 
neonate in the control group developed 
TTN versus none in the prostaglandin 
E2 group. However, this study has no 
significant impact as it could not assess 
any of the clinical neonatal outcomes 
due to its small sample size. The results 
of the current study might, therefore, be 
included in the next Cochrane 
reanalysis.  
In 2017, Khairy et al., in Egypt 
conducted a large RCT that included 
120 women to determine whether 
administration of prostaglandin E1 
(misoprostol) 200 mcg before ECS 
would decrease neonatal respiratory 
complications.11 The rate of TTN was 
significantly lower in the misoprostol 
group as compared with the control 
group (0% versus 21.7%, respectively; 
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p=0.000). Our study agreed with their 
results as the rate of TTN was 15.1% 
versus 26% in the misoprostol and 
control groups respectively (p=0.01). 
However, they. also found a significant 
decrease in the rate of admission to 
NICU and duration of NICU stay with 
misoprostol administration (p<0.001). 
Additionally, the Apgar scores at 1 and 5 
minutes were significantly lower in the 
misoprostol group (p=0.016 and 0.001 
respectively). Finally, no cases of RD 
occurred in the misoprostol group in 
their study.11 
These results contrast with those of our 
study. However, it should be noted that 
the dose of misoprostol used was 
different and the gestational age (≥at 38 
weeks) at ECS was later than in our 
study. Also, the larger sample size in the 
current study may have led to the 
difference in our results. We believe that 
using such a high dose of misoprostol 
(200 mcg) could be associated with 
serious maternal complications that 
outweigh its benefit. In the current study, 
the choice of using 50 mcg misoprostol 
was not associated with uterine 
hyperstimulation or scar dehiscence. 
The strengths of our study include that it 
was a RCT that included a large sample 
of women. Also, we were able to recruit 
our calculated sample so that we could 
achieve sufficient power to detect a 
clinically significant difference in our 
primary outcome. Finally, the use of 
misoprostol, which is inexpensive and 
has no major side effects compared with 
its proven benefits in neonatal 
respiratory outcomes, is another merit.  
The main limitation of our study was 
probably related to the lack of blinding of 
the surgeon and participants during 
randomization. However, the 
neonatologist who assessed the 
neonatal respiratory outcomes was 
blinded by the study group. Also, we did 
not compare neonatal outcome at 
different gestational ages in order to 
show the most beneficial time for 
misoprostol administration since the 
sample size did not allow subgroup 
analysis. Additionally, we did not 
measure the blood pH or catecholamine 
concentration in the umbilical cord 
arterial blood after delivery. Further 
studies are needed to confirm our 
results and to compare the effect of 
misoprostol on different gestational ages 
after 37 weeks. 
In conclusion, prophylactic vaginal 
misoprostol 50 mcg before elective CS 
at 34-37 weeks gestation reduces the 
rate of neonatal respiratory morbidity 
and could be an efficient way to prevent 
neonatal RD.  
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